JPMorgan Chase & Co. upgraded shares of United Therapeutics Corp. (NASDAQ:UTHR) from an underweight rating to a neutral rating in a research note issued to investors on Monday, TheFlyOnTheWall.com reports. The firm currently has $90.00 price target on the stock, up from their previous price target of $62.00. “wider choice of PAH therapies for physicians […]
JPMorgan Chase & Co. Upgrades United Therapeutics Corp. to Neutral (UTHR) is a post from: Zolmax
The post JPMorgan Chase & Co. Upgrades United Therapeutics Corp. to Neutral (UTHR) appeared first on Zolmax.
